Oyster Point Pharma (OYST) Stock Price, News & Analysis

Company Overview

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Key Stats

• Today's Range: $11.17 to $11.17
• 50-Day Range: $11.08 to $11.20
• 52-Week Range: $3.46 to $19.00
• Volume: 330 shs
• Average Volume: 212,171 shs
• Market Capitalization: $299.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OYST Stock Analysis - Frequently Asked Questions

How were Oyster Point Pharma's earnings last quarter?

Oyster Point Pharma, Inc. (NASDAQ:OYST) released its earnings results on Thursday, November, 4th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.48. The business had revenue of $17.94 million for the quarter. Oyster Point Pharma had a negative trailing twelve-month return on equity of 490.33% and a negative net margin of 901.99%.

When did Oyster Point Pharma IPO?

Oyster Point Pharma (OYST) raised $85 million in an IPO on Thursday, October 31st 2019. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray acted as the underwriters for the IPO.

What other stocks do shareholders of Oyster Point Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oyster Point Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OYST
• CIK: 1720725
• Web: www.oysterpointrx.com
• Phone: 609-382-9032
• Fax: N/A
• Employees: 303
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($6.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-100,660,000.00
• Net Margins: -901.99%
• Pretax Margin: -901.99%
• Return on Equity: -490.33%
• Return on Assets: -108.29%

Debt

• Debt-to-Equity Ratio: 8.49
• Current Ratio: 3.35
• Quick Ratio: 3.11

Sales & Book Value

• Annual Sales: $24.54 million
• Price / Sales: 12.22
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.80 per share
• Price / Book: 2.94

Miscellaneous

• Outstanding Shares: 26,844,000
• Free Float: 22,039,000
• Market Cap: $299.85 million
• Optionable: Not Optionable
• Beta: 1.31